'%2F%3E%3Cpath%20d%3D'M11%205H21M13.5%205V11.6A8.5%208.5%200%201%200%2018.5%2011.6V5'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'3.4'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Cpath%20d%3D'M10.6%2019.6L13.9%2021.8L17.6%2018.4L21.4%2020.4'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'2.6'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Ccircle%20cx%3D'17.6'%20cy%3D'18.4'%20r%3D'2.6'%20fill%3D'%23fff'%2F%3E%3C%2Fsvg%3E){kind=small}
Bliss GVS Pharma Limited
BLISSGVS (NSE) · BLISSGVS (BSE 506197) · ISIN INE416D01022 · Pharmaceuticals · Est. 1984 · listed 2010 · website
ASM Long term Stage 4 · BSE ASM Long term Stage 4 · NSE
In Q1 FY27 (quarter to 30 June 2026, standalone), revenue was ₹221.59 cr and profit after tax ₹38.62 cr. Revenue was 35.6% higher than in Q1 FY26.
Next: Board meeting: financial results on 29 October 2026.
Open the full company file Every section, filings and your notes, in the app.
Quarterly results
| Quarter | Revenue | Profit after tax | EPS (₹) | Filed |
|---|---|---|---|---|
| Q1 FY27 standalone | ₹221.59 cr | ₹38.62 cr | 3.58 | 12 Aug 2026 |
| Q4 FY26 standalone | ₹211.54 cr | ₹32.42 cr | 2.99 | 12 May 2026 |
| Q3 FY26 standalone | ₹164.68 cr | ₹18.61 cr | 1.72 | 10 Feb 2026 |
| Q2 FY26 standalone | ₹190.23 cr | ₹24.79 cr | 2.31 | 6 Nov 2025 |
| Q1 FY26 standalone | ₹163.36 cr | ₹21.05 cr | 1.98 | 29 Jul 2025 |
| Q4 FY25 standalone | ₹156 cr | ₹11.45 cr | 1.07 | 12 May 2025 |
| Q3 FY25 standalone | ₹511.2 cr | ₹57.52 cr | 5.43 | 29 Jan 2025 |
| Q2 FY25 standalone | ₹331.61 cr | ₹36.46 cr | 3.43 | 25 Oct 2024 |
Balance sheet
| As of | Total equity | Borrowings | Total assets |
|---|---|---|---|
| 31 Mar 2026 standalone | ₹1,155.19 cr | ₹0 cr | ₹1,344.18 cr |
| 30 Sep 2025 standalone | ₹1,103.68 cr | ₹35.58 cr | ₹1,305.93 cr |
| 31 Mar 2025 standalone | ₹1,058.63 cr | ₹51.01 cr | ₹1,219.7 cr |
Shareholding
| Promoter | FII | DII | Public |
|---|---|---|---|
| 35.01% | 8.07% | 9.47% | 64.99% |
Latest filings
- Annual Report FY2025-26 (New) 23 June 2026 · NSE
- Bliss GVS Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. 12 May 2026 · NSE
- Bliss GVS Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. 12 May 2026 · NSE
- The Board Meeting of Bliss GVS Pharma Limited ( the Company ) was held today i.e. Tuesday, February 10, 2026, at the registered office has considered and approved the following matter(s) amongst other 10 February 2026 · NSE
- Bliss GVS Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025. 6 November 2025 · NSE
Other companies in Pharmaceuticals
- Lupin Limited
- Sun Pharmaceutical Industries Limited
- Torrent Pharmaceuticals Limited
- Zydus Lifesciences Limited
- Ajanta Pharma Limited
- Alivus Life Sciences Limited
- Wockhardt Limited
- Morepen Laboratories Limited
Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 12 August 2026.
Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.